Sanofi’s Amlitelimab Shows Promising Phase IIb Results in Atopic Dermatitis, Potential for 12-Week Dosing
Sanofi (NASDAQ: SNY) announced this week promising results from a Phase IIb study of its...
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an...
Legend Biotech Reports Q4 and Full-Year 2023 Financials with Focus on Carvykti Milestones
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the fourth quarter and...
Gilead Nears Completion of CymaBay Acquisition After Waiting Period Expires
Gilead Sciences (NASDAQ: GILD) has moved one step closer to finalizing its cash tender offer...
J&J’s Tremfya Files for Ulcerative Colitis Indication with FDA, Building on Positive Late-Stage Data
The US Food and Drug Administration (FDA) has accepted an indication extension filing from Johnson...
Simcere Secures FDA Approval for Clinical Study of Trispecific Antibody SIM0500 in Multiple Myeloma
Simcere Pharmaceutical Group (HKG: 2096), based in China, has received approval from the U.S. Food...
Everest Medicines’ Velsipity NDA Accepted in Macau, Poised for First Asian Approval
Everest Medicines (HKG: 1952), based in China, has announced that its New Drug Application (NDA)...
Lepu Biotechnology’s MRG004A ADC Gains Fast Track Designation for Pancreatic Cancer
Lepu Biotechnology Co., Ltd. (HKG: 2157), based in China, has announced that its in-house developed...
Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has officially activated its licensing and cooperation agreement...
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...
ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval
Hangzhou Kang Ming Information Technology Co., Ltd. (HKG: 9955), known as “ClouDr,” has officially launched...
BeiGene Launches Legal Action Against Sandoz and MSN Over Brukinsa Patent Infringement
BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has initiated patent...
Eli Lilly Delays Donanemab Action Date as FDA Calls for Advisory Committee Review
Eli Lilly (NYSE: LLY) has announced a delay in the action date for its Alzheimer’s...
China Cracks Down on Medical Insurance Fraud with New Guidelines and Increased Prosecutions
China’s Supreme People’s Court, along with the Supreme People’s Procuratorate and the Ministry of Public...
FDA Approves Wegovy for Cardiovascular Risk Reduction in Obese Patients, First of Its Kind
The U.S. Food and Drug Administration (FDA) granted an indication extension approval last week to...
Amgen Reports Positive Results for Otezla in Pediatric Psoriasis Trial
Amgen (NASDAQ: AMGN) provided an update last week on a late-stage trial evaluating its PDE4...
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global...
GSK Reports US Adult Non-Flu Vaccination Rates Recover Post-Pandemic
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reported that...
BMS’s Opdivo Secures FDA Approval for First-Line Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
BeiGene’s Brukinsa Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biotech company based in China,...